Salicylamide O-acetic acid
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Salicylamide O-acetic acid is a salicylate indicated in combination with local anesthetics and corticosteroids for short term treatment of inflammation.
- Generic Name
- Salicylamide O-acetic acid
- DrugBank Accession Number
- DB16000
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 195.174
Monoisotopic: 195.053157774 - Chemical Formula
- C9H9NO4
- Synonyms
- 2-Carbamoylphenoxyacetic acid
- Salamidacetic acid
- Salicylamide-2-acetic acid
- External IDs
- 246-940-7
- NSC-65589
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Rheumesser 3 ml - Ampullen Salicylamide O-acetic acid (150 mg/3mL) + Cyanocobalamin (2.5 mg/3mL) + Dexamethasone (3.5 mg/3mL) + Kebuzone (450 mg/3mL) + Lidocaine (5 mg/3mL) Injection, solution Intramuscular G.L. Pharma Gmb H 1983-08-29 Not applicable Austria
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5LB8V0RHJV
- CAS number
- 25395-22-6
- InChI Key
- RLISWLLILOTWGG-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H9NO4/c10-9(13)6-3-1-2-4-7(6)14-5-8(11)12/h1-4H,5H2,(H2,10,13)(H,11,12)
- IUPAC Name
- 2-(2-carbamoylphenoxy)acetic acid
- SMILES
- NC(=O)C1=C(OCC(O)=O)C=CC=C1
References
- General References
- BASG: Rheumesser 3 ml - Ampullen (Cyanocobalamin, Dexamethason, Kebuzone, Lidocaine, Salicylamide O-acetic acid) Intramuscular Injection [Link]
- External Links
- ChemSpider
- 84035
- ChEBI
- 134850
- ChEMBL
- CHEMBL1700554
- ZINC
- ZINC000000051262
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.59 mg/mL ALOGPS logP 0.25 ALOGPS logP 0.14 Chemaxon logS -2.1 ALOGPS pKa (Strongest Acidic) 3.27 Chemaxon pKa (Strongest Basic) -0.94 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 89.62 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 47.68 m3·mol-1 Chemaxon Polarizability 18.28 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0a6r-0900000000-1ec720718ed46d63e6d8 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0zgi-0900000000-f2807064ea04ff0934cb Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0zi3-5900000000-948aac4ab8f1976ddf65 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-3900000000-68971c8b7cdfeb2e493e Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0pb9-0900000000-8ebe0dae6ce433f3f057 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9000000000-8b94da387a3e84f06189 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 147.093229 predictedDarkChem Lite v0.1.0 [M+H]+ 148.057129 predictedDarkChem Lite v0.1.0 [M+Na]+ 148.078429 predictedDarkChem Lite v0.1.0
Drug created at December 10, 2020 20:45 / Updated at May 05, 2021 20:32